Amedisys (NASDAQ:AMED) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Thursday.

AMED has been the subject of several other reports. Benchmark reaffirmed a “hold” rating on shares of Amedisys in a research report on Thursday, November 9th. Robert W. Baird reaffirmed a “hold” rating and set a $50.00 target price on shares of Amedisys in a research report on Wednesday, October 4th. Mizuho reaffirmed a “buy” rating and set a $65.00 target price (up from $55.00) on shares of Amedisys in a research report on Wednesday, November 8th. SunTrust Banks reaffirmed a “buy” rating and set a $70.00 target price on shares of Amedisys in a research report on Friday, November 10th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $60.00 target price on shares of Amedisys in a research report on Thursday, October 12th. One analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company’s stock. Amedisys currently has an average rating of “Hold” and a consensus price target of $61.00.

Shares of Amedisys (NASDAQ:AMED) traded up $0.23 during trading on Thursday, hitting $54.76. The stock had a trading volume of 337,048 shares, compared to its average volume of 320,680. Amedisys has a 1 year low of $43.07 and a 1 year high of $65.91. The stock has a market cap of $1,858.39, a price-to-earnings ratio of 43.81, a PEG ratio of 1.17 and a beta of 0.71. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.16.

Amedisys (NASDAQ:AMED) last announced its earnings results on Tuesday, November 7th. The health services provider reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.02. Amedisys had a return on equity of 14.68% and a net margin of 2.88%. The firm had revenue of $380.20 million during the quarter, compared to analyst estimates of $384.59 million. During the same period last year, the firm posted $0.36 EPS. The business’s revenue was up 5.1% compared to the same quarter last year. equities analysts forecast that Amedisys will post 2.24 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of AMED. Point72 Asset Management L.P. grew its stake in shares of Amedisys by 337.0% during the 3rd quarter. Point72 Asset Management L.P. now owns 474,044 shares of the health services provider’s stock worth $26,528,000 after acquiring an additional 674,044 shares during the period. American Century Companies Inc. raised its holdings in shares of Amedisys by 41.4% during the 3rd quarter. American Century Companies Inc. now owns 1,671,680 shares of the health services provider’s stock valued at $93,547,000 after buying an additional 489,220 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Amedisys by 29.7% during the 3rd quarter. Wells Fargo & Company MN now owns 1,484,041 shares of the health services provider’s stock valued at $83,048,000 after buying an additional 339,825 shares in the last quarter. Balyasny Asset Management LLC purchased a new position in shares of Amedisys during the 2nd quarter valued at about $7,736,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Amedisys by 10.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 846,575 shares of the health services provider’s stock valued at $47,375,000 after buying an additional 82,247 shares in the last quarter. Institutional investors own 94.44% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Amedisys (AMED) Downgraded by BidaskClub” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://theolympiareport.com/2018/01/14/amedisys-amed-downgraded-by-bidaskclub.html.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.